文章：

胶质母细胞瘤新兴疗法

Emerging Therapies for Glioblastoma

原文发布日期：12 April 2024

DOI: 10.3390/cancers16081485

类型: Article

开放获取: 是

英文摘要：

Glioblastoma is most commonly a primary brain tumor and the utmost malignant one, with a survival rate of approximately 12–18 months. Glioblastoma is highly heterogeneous, demonstrating that different types of cells from the same tumor can manifest distinct gene expression patterns and biological behaviors. Conventional therapies such as temozolomide, radiation, and surgery have limitations. As of now, there is no cure for glioblastoma. Alternative treatment methods to eradicate glioblastoma are discussed in this review, including targeted therapies to PI3K, NFKβ, JAK-STAT, CK2, WNT, NOTCH, Hedgehog, and TGFβ pathways. The highly novel application of oncolytic viruses and nanomaterials in combating glioblastoma are also discussed. Despite scores of clinical trials for glioblastoma, the prognosis remains poor. Progress in breaching the blood–brain barrier with nanomaterials and novel avenues for targeted and combination treatments hold promise for the future development of efficacious glioblastoma therapies.

摘要翻译： 

胶质母细胞瘤通常为原发性脑肿瘤，且恶性程度最高，患者生存期约为12-18个月。该肿瘤具有高度异质性，同一肿瘤中不同类型的细胞可呈现差异化的基因表达模式与生物学行为。替莫唑胺、放疗及手术等传统疗法存在局限性，目前胶质母细胞瘤尚无根治手段。本综述探讨了针对PI3K、NFKβ、JAK-STAT、CK2、WNT、NOTCH、Hedgehog及TGFβ信号通路的靶向治疗等新型治疗方案，同时论述了溶瘤病毒与纳米材料在对抗胶质母细胞瘤中的创新应用。尽管已有大量临床试验，胶质母细胞瘤的预后仍不理想。纳米材料在突破血脑屏障方面的进展，以及靶向治疗与联合治疗的新途径，为未来开发有效的胶质母细胞瘤疗法带来了希望。

原文链接：

Emerging Therapies for Glioblastoma